open access

Vol 57, No 4 (2006)
Original papers
Published online: 2006-07-07
Submitted: 2013-02-15
Get Citation

Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms

Magdalena Bogdańska, Barbara Górnicka, Bogna Ziarkiewicz-Wróblewska, Łukasz Koperski, Marcin Morton, Aleksander Wasiutyński
Endokrynologia Polska 2006;57(4):314-319.

open access

Vol 57, No 4 (2006)
Original papers
Published online: 2006-07-07
Submitted: 2013-02-15

Abstract

Introduction: Estimation of malignancy in thyroid follicular neoplasms is a common diagnostic problem, thus revealing of differences in expression of some antigens in both benign and malignant lesions seems to be essential. The aim of this study is to evaluate the immunohistochemical expression of CD15, galectin-3 and HBME-1 in follicular adenomas and carcinomas.
Material and methods: Samples of 38 follicular adenomas (23 "classical", 5 with intracapsular invasion, 10 oncocytic) and 15 follicular carcinomas (9 "classic", 6 oncocytic) were stained immunohistochemically with anti-CD15, galectin-3 and HBME-1.
Results: In the whole group we found statistically significant differences in CD15 expression between follicular adenomas and carcinomas. "Classic" follicular carcinomas (without oncocytic tumors) showed stronger CD15 and HBME- 1 expression than "classic" adenomas. Adenomas with intracapsular invasion differed from "classic" adenomas only in HBME-1 expression. In oncocytic tumors the expression of examined antigens was similar.
Conclusions: 1. In the group of nonoxyphilic tumors positive reaction with HBME-1 was more common in adenomas with intracapsular invasion and carcinomas, but positive reaction with anti-CD15 - only in carcinomas. We suggest that reactivity with these antibodies could mark malignancy.
2. Oncocytic tumors had similar expression of CD15 and HBME-1 and galectin-3.

Abstract

Introduction: Estimation of malignancy in thyroid follicular neoplasms is a common diagnostic problem, thus revealing of differences in expression of some antigens in both benign and malignant lesions seems to be essential. The aim of this study is to evaluate the immunohistochemical expression of CD15, galectin-3 and HBME-1 in follicular adenomas and carcinomas.
Material and methods: Samples of 38 follicular adenomas (23 "classical", 5 with intracapsular invasion, 10 oncocytic) and 15 follicular carcinomas (9 "classic", 6 oncocytic) were stained immunohistochemically with anti-CD15, galectin-3 and HBME-1.
Results: In the whole group we found statistically significant differences in CD15 expression between follicular adenomas and carcinomas. "Classic" follicular carcinomas (without oncocytic tumors) showed stronger CD15 and HBME- 1 expression than "classic" adenomas. Adenomas with intracapsular invasion differed from "classic" adenomas only in HBME-1 expression. In oncocytic tumors the expression of examined antigens was similar.
Conclusions: 1. In the group of nonoxyphilic tumors positive reaction with HBME-1 was more common in adenomas with intracapsular invasion and carcinomas, but positive reaction with anti-CD15 - only in carcinomas. We suggest that reactivity with these antibodies could mark malignancy.
2. Oncocytic tumors had similar expression of CD15 and HBME-1 and galectin-3.
Get Citation

Keywords

thyroid follicular carcinoma; thyroid follicular adenoma; CD15; galectin-3; HBME-1

About this article
Title

Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms

Journal

Endokrynologia Polska

Issue

Vol 57, No 4 (2006)

Pages

314-319

Published online

2006-07-07

Bibliographic record

Endokrynologia Polska 2006;57(4):314-319.

Keywords

thyroid follicular carcinoma
thyroid follicular adenoma
CD15
galectin-3
HBME-1

Authors

Magdalena Bogdańska
Barbara Górnicka
Bogna Ziarkiewicz-Wróblewska
Łukasz Koperski
Marcin Morton
Aleksander Wasiutyński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl